| Literature DB >> 34322362 |
Sujata Tripathi1, Amit Mishra2, Vijay C Popat3, Syed Altaf Husain4.
Abstract
Wilms' tumor (WT) in adults is a rare neoplasm. Only a few reports are available in the literature. The tumor often masquerades as renal cell carcinoma (RCC). For accurate reporting, histopathological examination (HPE) plays a vital role in early diagnosis and prompt administration of multimodality treatment helps to improve the prognosis. We comprehensively analyzed five cases of adult WT presenting in the third to fifth decade with flank pain, hematuria, fever, and palpable lump. After complete clinical, biochemical, radiological, and HPE evaluation, tumor was staged and treatment was planned accordingly. Patients with low-stage WT were treated with open radical nephrectomy and chemotherapy. One of the patients diagnosed with inferior vena cava (IVC) thrombus apart from the above treatment also underwent IVC thrombectomy. Another young male presenting with distant metastasis (stage IV) and focal anaplasia on histology received preoperative chemotherapy and then planned for surgery. Unfortunately, the tumor being unresectable, second-line chemotherapy was given but he ultimately succumbed to death. All other patients are on regular follow-up and disease-free. Adult nephroblastoma is a rare clinical entity with hostile behavior. The presence of IVC thrombus is not a contraindication to surgery. Although the management strategy as per pediatric protocol by the inclusion of multimodality approach improves survival, still the overall prognosis in adults is dismal. There is a need for a standardized treatment protocol to encourage a homogenous approach for this rare disease and thereby improve survival. Copyright: Sujata T, et al.Entities:
Keywords: NWTS; SIOP; adult Wilms’ tumor; inferior vena cava; nephroblastoma; thrombus
Year: 2021 PMID: 34322362 PMCID: PMC8297498 DOI: 10.15586/jkcvhl.v8i2.186
Source DB: PubMed Journal: J Kidney Cancer VHL ISSN: 2203-5826
Showing the clinical, radiological, therapeutic, and histopathological details of the cases included in our study.
| Case no. | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| 34/M, pain, fever, hematuria, and palpable lump–3 months | 25/M, painless lump, abdominal discomfort, vomiting – 4 months | 37/F, Pain, hematuria, hard palpable lump – 6 months | 40/M, Pain, hematuria, B/L pedal edema, anemia – 3 months | 24/M, Pain, hematuria, weight loss, decreased KPS, palpable lump—5 months | |
| RK, LP mass (19 × 13 × 22 cm), heterogenous hypointense on T2WMRI | RK, LP mass (17 × 16 × 12), calcification, hypodense on CT No contrast enhancement | LK, UP mass (13 × 12 × 10cm), hypodense, heterogenous, with thin peripheral enhance ment on CT | LK, MP & LP mass (10 × 6 × 7), hyperint ense, heterogenous on T2W MRI, with renal vein and IVC thrombus (Level II) | L.K., (16 × 15 × 16 cm) lobulated, heterogenous, hypodense mass on CT, multiple lymph nodes, few liver and lung mets | |
| Right open radical nephrectomy followed by chemotherapy | Right open radical nephrectomy followed by chemotherapy | Left open radical nephrectomy followed by chemotherapy | Left open radical nephrectomy with IVC thrombectomy and regional lymphadenectomy followed by chemotherapy | Preoperative chemotherapy but found unresectable, so second-line chemotherapy, succumbed to death. | |
| Triphasic, WT1 +ve, stroma vimentin +ve, CD 10-ve, No anaplasia. | Marked calcifica tions, triphasic, vimentin +ve, WT1 +ve. No anaplasia. | Triphasic Wilms, WT1 +ve cells, vimentin +ve. No anaplasia | Highly cellular with predominant blastemal elements, spindle cells WT1 +ve, Vimentin +ve, No anaplasia | Triphasic pattern, predominant undifferentiated blastemal cells WT1 +ve, vimentin +ve with focal anaplastic cells | |
| 0 | 0 | 0 | 1 | 2 | |
| I | I | I | II | IV | |
| I | Nil | II | II, IIIa | – | |
| Lost to FUP | 84 | On chemo since 4 months | 60 | Mortality |
RK: Right kidney; LK: Left kidney; M: Male; F: Female; KPS: Karnofsky performance score; B/L: Bilateral; UP: Upper pole; MP: Midpole; LP: Lower pole; MRI: magnetic resonance imaging, CT: Computed tomography; IVC: Inferior vena cava; ECOG: Eastern Cooperative Oncology Group; chemo: chemotherapy; FUP: Follow up.
Figure 1MRI of the abdomen and pelvis showing heterogenous hypointense large right renal mass, arising from lower pole, fat plane maintained with liver, IVC compressed by mass and pushed laterally.
Figure 2:MRI of the abdomen and pelvis showing left renal mass, renal vein, and IVC thrombus.
Figure 3:(A) Histopathological examination (HPE) of specimen from first patient showing features of Wilms’ tumor, 40× magnification. (B) HPE of specimen from second patient showing epithelial and stromal component of Wilms’ tumor. Black star highlights epithelial component and red star highlights stromal component, 100× magnification. (C) HPE of specimen from third patient showing blastemal component highlighted by red star, 200× magnification. (D) HPE of specimen from fourth patient showing only blastemal component, 400× magnification.
Figure 4:(A) Tumor cells are positive for vimentin on immunohistochemistry, 10× magnification. (B) Tumor cells are positive for WT-1 on immunohistochemistry, 10× magnification.
Management as per NWTS protocol.
| Management as per NWTS protocol | ||
|---|---|---|
| Stage | Histology | Treatment |
| I | Favorable | 18 weeks of ACT/VCR |
| Unfavorable | ||
| II | Favorable | 18 weeks of ACT/VCR |
| III | Favorable | 24 weeks of ACT/VCR/ADM, RT tumor bed + involved sites |
| IV | Favorable | |
| II–IV | Unfavorable | 24 weeks of ACT/VCR/ADM/CTX/Etoposide, RT tumor bed + involved sites |
ACT: Actinomycin D; VCR: Vincristine; ADM: Adriamycin (Doxorubicin); RT: Radiotherapy; CTX: Cyclophosphamide; NWTS: National Wilms Tumor Study group.
Review of literature illustrating comparable clinicopathological treatment and outcome variables.
| Study groups | Reinhard et al. (2004) | Mitry et al. (2004) | Izawa et al. (2008) | Kalapurkal et al. (2004) | Kattan et al. (1994) | Our study |
|---|---|---|---|---|---|---|
| Variables ↓ | ||||||
| 25.4 | 34 | 26 | 21.9 | 24 | 32 | |
| 30 | 133 | 128 | 23 | 22 | 5 | |
| Pain, palpable lump, gross hematuria | NIA | NIA | NIA | Pain, hematuria, abdominal mass | Pain, hematuria, abdominal mass | |
| 18 Rt:10 Lt, 2 Extrarenal | NIA | NIA | NIA | Rt (14), Lt (8) | Rt(2), Lt(3) | |
| 66% localized, 33% metastatic | 23% -loco regional, 10% metastatic, | NIA | Stage I/II-13, Stage≥III-10 | Stage I/II-12, Stage≥III-10 | Stage I-3 | |
| Surgery only (3), Neoadjuvant CT (4) | NIA | Surgery, CT (120), CT+RT (77), No T/t- 7, NIA -1 | Surgery, | Multimodal (15), Adjuvant CT (6), | Surgery (4), CT (5) | |
| Blastemal predominant (M.C.), Mixed (CCSK), Stromal or epithelial | NIA | NIA | NIA | FH (21), UFH (1) | FH (4), UFH (1) | |
| 48 | 60 | 54 | 61 | 100 | 120 | |
| 5 | NIA | NIA | NIA | 10 | 1 |
Rt: Right; Lt: Left; NIA: No information available; CT: Chemotherapy; RT: Radiotherapy; T/t: Treatment; M.C.: Most common; CCSK: Clear cell sarcoma of kidney; M/F: Male/Female; FUP: Follow up; FH: Favorable histology; UFH: Unfavorable histology; HPE: Histopathological examination; O.S.: Overall survival.